Pharmacokinetics of Digoxin: Interpreting Bioavailability

Pharmacokinetics of digoxin: interpreting bioavailability.

Three subjects were first given a digoxin tablet in the fasting state and subsequently received the same formulation in the fed state, to simulate a spurious oral bioavailability difference. As expected, when measured by peak serum digoxin concentration as well as by area under the serum digoxin concentration-time curve the bioavailability of digoxin appeared to be higher in the fasting state t...

Digitalis-like factors and digoxin pharmacokinetics.

Decreased bioavailability of digoxin due to hypocholesterolemic interventions.

This study tested the hypothesis that hypocholesterolemic interventions interfere with the bioavailability of orally administered digoxin. Using single dose studies of bioavailability, cumulative six-day urinary digoxin excretion (expressed as a percentage of each individual's control value) was 103% with a normal fiber diet, 82% with a high fiber diet, 83% with 4 g of cholestyramine, 69% with ...

Pharmacokinetics, Biodistribution and Bioavailability of Liposomal Drugs

Stealth liposomal doxorubicin (Doxil ® /Caelyx ®) passively targets to tumors through the enhanced permeability and retention (EPR) effect, which is a result of enhanced vascular permeability of tumor blood vessels. The endothelial lining of the diseased site contains gaps that can range from 380-780 nm which are large enough for the extravasation of liposomes (~100 nm). Once the liposomes are ...

Effects of sheep digoxin-specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs.

Intact sheep antidigoxin antibodies and their Fab fragments have both been found to exert profound effects on digoxin pharmacokinetics in [3H] digoxin-treated dogs. Both classes of molecule remove digoxin from the extravascular space and sequester it in the circulation in protein-bound form, a form in which the digoxin is presumably inactive. These two classes of molecule differ, however, in th...